ofloxacin has been researched along with omeprazole in 50 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (2.00) | 18.2507 |
2000's | 28 (56.00) | 29.6817 |
2010's | 21 (42.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Aeschlimann, JR; Kaatz, GW; Rybak, MJ | 1 |
Arancio, F; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Cuoco, L; Gasbarrini, A; Gasbarrini, G; Pirozzi, G; Santarelli, L; Zocco, MA | 1 |
Hassan, C; Lorenzetti, R; Morini, S; Zullo, A | 1 |
Bermejo, MV; Cantón, E; Orero, A; Pemán, J; Velert, MM | 1 |
Chan, CK; Fung, FM; Gu, Q; Hu, WH; Lai, KC; Lam, SK; Wong, BC; Wong, WM; Xia, HH; Yee, YK; Yuen, MF | 1 |
Angeletti, S; De Francesco, V; Hassan, C; Ierardi, E; Lorenzetti, R; Marignani, M; Morini, S; Zullo, A | 1 |
Asaumi, N; Kiguchi, T; Masuda, K; Niiya, K; Niiya, M; Tanimoto, M; Yoshida, C | 1 |
Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
Asaumi, N; Niiya, K; Niiya, M; Shibakura, M; Tanimoto, M; Yoshida, C | 1 |
Aoyama, N; Fukuda, M; Kachi, M; Kasuga, M; Kuroda, K; Maekawa, S; Miki, I; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A | 1 |
Blancas-Valencia, JM; Bosques-Padilla, FJ; Calderón-Lozano, IE; de Ariño Suárez, M; Garza-González, E; Orozco-Gámiz, A; Reed-SanRoman, G; Tamayo-de la Cuesta, JL; Valdovinos-Díaz, MA | 1 |
Accornero, L; Bilardi, C; Dulbecco, P; Iiritano, E; Mamone, M; Mansi, C; Parodi, A; Reglioni, S; Savarino, E; Savarino, V; Vigneri, S; Zentilin, P | 1 |
Castro, LP; Cerqueira, MC; Cindr, JM; Coelho, LG; Gallo, MA; Mendonça, S; Moretzsohn, LD; Passos, MC; Pedrazzoli-Júnior, J; Ribeiro, ML; Vieira, WL; Vitiello, L | 1 |
Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R | 2 |
Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A | 1 |
Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P | 1 |
Almela, P; Barrio, J; Benito, LM; Bermejo, F; Bory, F; Calvet, X; Carneros, JA; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Franco, A; García-Durán, F; Gisbert, JP; Khorrami, S; Lamas, E; Modolell, I; Niño, P; O'Callaghan, E; Ortiz, V; Ortuño, J; Pérez-Aisa, A; Ponce, J; Rodrigo, L; Sánchez-Pobre, P; Tomas, A; Valer, MP | 1 |
Cantu, M; Ferguson, D; Page, RL | 1 |
García-Pérez, FJ; Reina, MT; Sánchez-Cuéllar, S | 1 |
Andrés, PR; Bermejo, AB; Bermejo, MF; Gallardo, BP; García, GG; Gisbert, JP; Infante, JM; Rodríguez, JM | 1 |
Barrio, J; Castro-Fernández, M; Cosme, A; Gisbert, JL; Gisbert, JP; Marcos, S; Moreno-Otero, R; Pérez-Aisa, A; Rodrigo, L | 1 |
Abadia, EG; Dueñas, C; Fernandez-Bermejo, M; Gisbert, JP; Gonzalez-Garcia, G; Hernandez-Alonso, M; Mateos-Rodriguez, JM; Molina-Infante, J; Perez-Gallardo, B; Vinagre, G | 1 |
Azad, MA; Faruquee, CF; Hasnat, A; Parveen, S; Rayhan, I; Ullah, A | 1 |
Cristofari, F; De Francesco, V; Hassan, C; Manes, G; Scaccianoce, G; Zullo, A | 1 |
Abdelfatah, M; Assem, M; El Azab, G; Rasheed, MA; Shastery, M | 1 |
Li, W; Shen, LY; Ye, LP; Zhang, J | 1 |
Acheampong, A; Ellis, R; Ni, J; Ouyang, H; Rowe, J; Sakuma, T; Seto, C; Szekely-Klepser, G; Welty, D | 1 |
Choi, KH; Chung, WC; Jung, SH; Kang, BK; Kim, EJ; Lee, KM; Oak, JH; Paik, CN | 1 |
Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A | 1 |
Basu, PP; Flynn, M; Krishnaswamy, N; Pacana, T; Rayapudi, K; Shah, NJ | 1 |
Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL | 1 |
Almela, P; Barrio, J; Bermejo, F; Bory, F; Calvet, X; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Franco, A; Gisbert, JP; Guerra, I; Khorrami, S; Lamas, E; Modolell, I; Ortuño, J; Pérez-Aisa, A; Ponce, J; Rodrigo, L; Sánchez-Pobre, P; Tomas, A | 1 |
Akyuz, F; Ermis, F; Mungan, Z | 1 |
Bizzarri, B; de'Angelis, GL; Manfredi, M | 1 |
Camacho-Muñoz, D; Kasprzyk-Hordern, B; Thomas, KV | 1 |
1 review(s) available for ofloxacin and omeprazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 trial(s) available for ofloxacin and omeprazole
Article | Year |
---|---|
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Tinidazole | 2000 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Rifabutin; Treatment Outcome | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mexico; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Time Factors; Treatment Outcome | 2004 |
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Pantoprazole; Prospective Studies; Sulfoxides; Treatment Outcome | 2004 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Time Factors; Tinidazole; Treatment Outcome | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Tinidazole; Treatment Outcome | 2006 |
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure; Urea | 2008 |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Single-Blind Method; Young Adult | 2010 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Peptic Ulcer; Prospective Studies; Rifamycins; Rifaximin | 2011 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Peptic Ulcer; Treatment Outcome; Young Adult | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Levofloxacin; Male; Middle Aged; Nitro Compounds; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Thiazoles; Young Adult | 2011 |
Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Treatment Outcome; Young Adult | 2012 |
32 other study(ies) available for ofloxacin and omeprazole
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Multidrug Resistance-Associated Proteins; Norfloxacin; Ofloxacin; Omeprazole; Species Specificity; Staphylococcal Infections; Staphylococcus aureus | 1999 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Benzimidazoles; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Ofloxacin; Omeprazole; Rabeprazole | 2001 |
[Influence of ion pump-inhibiting drugs on the accumulation of ofloxacin and grepafloxacin in human polymorphonuclear leukocytes].
Topics: Anti-Infective Agents; Calcium Channel Blockers; Digoxin; Enzyme Inhibitors; Fluoroquinolones; Humans; Ion Pumps; Neutrophils; Ofloxacin; Omeprazole; Piperazines; Verapamil | 2002 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glossitis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Blood Platelets; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure | 2003 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Benzimidazoles; Drug Combinations; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Treatment Outcome | 2005 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Comorbidity; Drug Therapy, Combination; Heart Failure; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Proton Pump Inhibitors | 2008 |
[Streptococcus pneumoniae infection: cause or consequence of pulmonary alveolar proteinosis?].
Topics: Drug Therapy, Combination; Humans; Male; Middle Aged; Ofloxacin; Omeprazole; Pneumonia, Pneumococcal; Pregnenediones; Pulmonary Alveolar Proteinosis; Remission Induction; Tomography, X-Ray Computed | 2008 |
Levofloxacin, Amoxicillin, and Omeprazole as first-line triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Patient Compliance; Treatment Outcome | 2009 |
Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Treatment Outcome | 2010 |
Interaction study between levofloxacin and omeprazole using urinary pharmacokinetic data.
Topics: Adolescent; Adult; Drug Interactions; Female; Humans; Levofloxacin; Male; Ofloxacin; Omeprazole; Time Factors | 2010 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Time Factors; Treatment Failure | 2010 |
Iatrogenic gastric wall abscess infected with Enterobacter cloacae after biopsy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Digestive System; Enterobacter cloacae; Enterobacteriaceae Infections; Gastritis; Humans; Iatrogenic Disease; Male; Ofloxacin; Omeprazole; Pyloric Antrum | 2010 |
Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.
Topics: Animals; Atorvastatin; Chromatography, Liquid; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Metabolome; Ofloxacin; Omeprazole; Pharmacokinetics; Pyrroles; Rats; Rats, Sprague-Dawley; Tamoxifen; Tandem Mass Spectrometry | 2010 |
Safety profile of enantiomers vs. racemic mixtures: it's the same?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cetirizine; Citalopram; Databases, Factual; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Stereoisomerism; Young Adult | 2012 |
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Spain; Surveys and Questionnaires; Time Factors; Treatment Failure | 2013 |
Recurrence of Helicobacter pylori After Eradication in Patients with Peptic Ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Ofloxacin; Omeprazole | 2012 |
Enantioselective simultaneous analysis of selected pharmaceuticals in environmental samples by ultrahigh performance supercritical fluid based chromatography tandem mass spectrometry.
Topics: Aminorex; Carbazoles; Chloramphenicol; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; Flurbiprofen; Humans; Ibuprofen; Ifosfamide; Imidazoles; Indoprofen; Molecular Structure; Naproxen; Ofloxacin; Omeprazole; Praziquantel; Solid Phase Extraction; Stereoisomerism; Tandem Mass Spectrometry; Tetramisole; Water Pollutants, Chemical | 2016 |